Physician profile
Christopher Ryan Oxner
NPI 1801086129
$34,090.59
in general payments reported to CMS, 2019-2025
15 companies · $261 in 2025
The $261 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $178 · 2021: $21K · 2022: $11K · 2023: $234 · 2024: $930 · 2025: $261.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $793 · Travel and Lodging: $633.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $792.57 |
| Travel and Lodging | $632.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $31,673.48 | 2021-2025 | Da Vinci Surgical System |
| Stryker Corporation | $1,044.54 | 2021-2023 | Spy-Phi System |
| Histosonics, INC. | $706.82 | 2024 | |
| Covidien LP | $177.69 | 2020 | |
| Angiodynamics, INC. | $119.70 | 2025 | Nanoknife |
| Intera Oncology, INC | $106.78 | 2024 | Intera |
| Astellas Pharma US INC | $45.96 | 2024 | Xospata |
| Merck Sharp & Dohme LLC | $40.81 | 2024-2025 | Keytruda, Keytruda Qlex |
| Lexington Medical, INC. | $33.58 | 2023 | Aeon Endostapler & Echelon Flex Powered Stapler |
| Astrazeneca Pharmaceuticals LP | $28.43 | 2025 | Imfinzi |
| Incyte Corporation | $26.68 | 2025 | Monjuvi, Zynyz |
| Geron Corporation | $24.01 | 2025 | Rytelo |
| Eisai INC. | $22.73 | 2025 | |
| Beigene USA, INC. | $20.42 | 2024 | Tevimbra |
| Regeneron Healthcare Solutions, INC. | $18.96 | 2023 | Libtayo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Oxner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.